RU2018145507A3 - - Google Patents

Download PDF

Info

Publication number
RU2018145507A3
RU2018145507A3 RU2018145507A RU2018145507A RU2018145507A3 RU 2018145507 A3 RU2018145507 A3 RU 2018145507A3 RU 2018145507 A RU2018145507 A RU 2018145507A RU 2018145507 A RU2018145507 A RU 2018145507A RU 2018145507 A3 RU2018145507 A3 RU 2018145507A3
Authority
RU
Russia
Application number
RU2018145507A
Other languages
Russian (ru)
Other versions
RU2018145507A (ru
RU2762939C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59315675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2018145507(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of RU2018145507A publication Critical patent/RU2018145507A/ru
Publication of RU2018145507A3 publication Critical patent/RU2018145507A3/ru
Application granted granted Critical
Publication of RU2762939C2 publication Critical patent/RU2762939C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y203/00Acyltransferases (2.3)
    • C12Y203/02Aminoacyltransferases (2.3.2)
    • C12Y203/02013Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/522CH1 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018145507A 2016-06-10 2017-06-12 Конъюгированные с лизином иммуноглобулины RU2762939C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348410P 2016-06-10 2016-06-10
US62/348,410 2016-06-10
PCT/JP2017/021672 WO2017213267A1 (en) 2016-06-10 2017-06-12 Lysine conjugated immunoglobulins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021136863A Division RU2021136863A (ru) 2016-06-10 2017-06-12 Конъюгированные с лизином иммуноглобулины

Publications (3)

Publication Number Publication Date
RU2018145507A RU2018145507A (ru) 2020-07-10
RU2018145507A3 true RU2018145507A3 (cg-RX-API-DMAC7.html) 2020-10-15
RU2762939C2 RU2762939C2 (ru) 2021-12-24

Family

ID=59315675

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018145507A RU2762939C2 (ru) 2016-06-10 2017-06-12 Конъюгированные с лизином иммуноглобулины
RU2021136863A RU2021136863A (ru) 2016-06-10 2017-06-12 Конъюгированные с лизином иммуноглобулины

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2021136863A RU2021136863A (ru) 2016-06-10 2017-06-12 Конъюгированные с лизином иммуноглобулины

Country Status (21)

Country Link
US (2) US10941431B2 (cg-RX-API-DMAC7.html)
EP (1) EP3468614A1 (cg-RX-API-DMAC7.html)
JP (1) JP7041077B2 (cg-RX-API-DMAC7.html)
KR (1) KR102538866B1 (cg-RX-API-DMAC7.html)
CN (1) CN109475642B (cg-RX-API-DMAC7.html)
AU (1) AU2017279352B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018075253A2 (cg-RX-API-DMAC7.html)
CA (1) CA3026991A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003383A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018013314A2 (cg-RX-API-DMAC7.html)
IL (1) IL263329B (cg-RX-API-DMAC7.html)
JO (1) JOP20180118A1 (cg-RX-API-DMAC7.html)
MX (1) MX419566B (cg-RX-API-DMAC7.html)
MY (1) MY202858A (cg-RX-API-DMAC7.html)
NZ (1) NZ748605A (cg-RX-API-DMAC7.html)
PE (1) PE20190340A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018502594A1 (cg-RX-API-DMAC7.html)
RU (2) RU2762939C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201810470XA (cg-RX-API-DMAC7.html)
UA (1) UA126799C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017213267A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2747581C2 (ru) 2015-12-18 2021-05-11 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Конъюгированные иммуноглобулины с c-концевым лизином
SG11201810470XA (en) 2016-06-10 2018-12-28 Eisai R&D Man Co Ltd Lysine conjugated immunoglobulins
CN114702587A (zh) * 2019-05-09 2022-07-05 美勒斯公司 用于使蛋白质多聚化的变体结构域及其分离
GB201907093D0 (en) * 2019-05-20 2019-07-03 Ucl Business Plc Antibody functionalisation
JP7664943B2 (ja) * 2020-03-25 2025-04-18 イーライ リリー アンド カンパニー 多重特異性結合タンパク質およびそれを開発する方法
BR112022023557A2 (pt) 2020-05-20 2022-12-20 Janssen Biotech Inc Métodos para conjugação sítio-específica de proteínas contendo domínios fc glicosilados
AU2021350011A1 (en) * 2020-09-25 2023-05-11 Epivax, Inc. Retro-inverso regulatory t cell epitopes
EP4392454A4 (en) * 2021-08-27 2025-10-15 Janssen Biotech Inc ANTI-PSMA ANTIBODIES AND THEIR USES
CN117164701A (zh) * 2022-12-27 2023-12-05 优洛生物(上海)有限公司 一种经改造的抗体、其制备方法及其用途
EP4673474A2 (en) 2023-02-28 2026-01-07 Eisai R&D Management Co., Ltd. Anti-psma antibodies, conjugates, and methods of use
US20240337664A1 (en) * 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Characterization of crosslinking sites in antibody-drug conjugates
CN119375471A (zh) * 2023-07-26 2025-01-28 菲鹏生物股份有限公司 抗体和抗体缀合物及其用途
WO2025199464A1 (en) 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Anti-trop2 antibody-drug conjugates and methods of use
CN120779021A (zh) * 2024-04-08 2025-10-14 菲鹏生物股份有限公司 抗体缀合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
CA2552043A1 (en) * 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
CA2813411C (en) * 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2013176516A1 (ko) 2012-05-24 2013-11-28 한화케미칼 주식회사 트랜스글루타미나아제를 이용하여 제조한 항체-약물 결합체 및 이의 용도
EP2916872B1 (en) * 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
CN105517577A (zh) * 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
EP3019515B1 (en) * 2013-07-11 2019-08-21 Novartis AG Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
CA2919583C (en) * 2013-07-31 2018-09-11 Rinat Neuroscience Corp. Engineered polypeptide conjugates
CN106456798B (zh) 2014-04-25 2021-02-12 瑞纳神经科学公司 具有高药物负载的抗体-药物缀合物
RU2747581C2 (ru) * 2015-12-18 2021-05-11 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Конъюгированные иммуноглобулины с c-концевым лизином
SG11201810470XA (en) 2016-06-10 2018-12-28 Eisai R&D Man Co Ltd Lysine conjugated immunoglobulins

Also Published As

Publication number Publication date
US10941431B2 (en) 2021-03-09
MX419566B (es) 2025-01-14
RU2021136863A (ru) 2022-02-01
CN109475642B (zh) 2023-05-02
RU2018145507A (ru) 2020-07-10
CN109475642A (zh) 2019-03-15
IL263329A (en) 2018-12-31
CO2018013314A2 (es) 2019-02-19
EP3468614A1 (en) 2019-04-17
PH12018502594A1 (en) 2019-10-14
WO2017213267A1 (en) 2017-12-14
KR102538866B1 (ko) 2023-06-02
BR112018075253A2 (pt) 2019-04-30
MY202858A (en) 2024-05-25
IL263329B (en) 2022-05-01
US11753669B2 (en) 2023-09-12
JP7041077B2 (ja) 2022-03-23
AU2017279352B2 (en) 2024-07-25
US20180044711A1 (en) 2018-02-15
JP2019525897A (ja) 2019-09-12
KR20190018159A (ko) 2019-02-21
AU2017279352A1 (en) 2018-12-13
MX2018015331A (es) 2019-08-16
PE20190340A1 (es) 2019-03-07
RU2762939C2 (ru) 2021-12-24
CA3026991A1 (en) 2017-12-14
NZ748605A (en) 2023-05-26
CL2021003383A1 (es) 2022-08-19
US20210171998A1 (en) 2021-06-10
UA126799C2 (uk) 2023-02-08
JOP20180118A1 (ar) 2019-01-30
SG11201810470XA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
BR112019009262A2 (cg-RX-API-DMAC7.html)
BR112019000402A2 (cg-RX-API-DMAC7.html)
BR112018071172A2 (cg-RX-API-DMAC7.html)
BR112019009373A2 (cg-RX-API-DMAC7.html)
BR112019003108A2 (cg-RX-API-DMAC7.html)
BE2016C036I2 (cg-RX-API-DMAC7.html)
CN303541740S (cg-RX-API-DMAC7.html)
CN303537759S (cg-RX-API-DMAC7.html)
CN303536126S (cg-RX-API-DMAC7.html)
CN303536221S (cg-RX-API-DMAC7.html)
CN303561737S (cg-RX-API-DMAC7.html)
CN303536241S (cg-RX-API-DMAC7.html)
CN303536262S (cg-RX-API-DMAC7.html)
CN303536272S (cg-RX-API-DMAC7.html)
CN303536511S (cg-RX-API-DMAC7.html)
CN303536541S (cg-RX-API-DMAC7.html)
CN303536542S (cg-RX-API-DMAC7.html)
CN303536616S (cg-RX-API-DMAC7.html)
CN303537182S (cg-RX-API-DMAC7.html)
CN303537318S (cg-RX-API-DMAC7.html)
CN303537475S (cg-RX-API-DMAC7.html)
CN303537476S (cg-RX-API-DMAC7.html)
CN303537528S (cg-RX-API-DMAC7.html)
CN303537545S (cg-RX-API-DMAC7.html)
CN303537688S (cg-RX-API-DMAC7.html)